Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohnʼs Disease Refractory to Anti-Tumor Necrosis Factor Agents - Wils, P; Bouhnik, Y; Michetti, P (Clin Gastroenterol Hepatol, 2016)
e241–242